Researchers at the University Hospital Bonn (UKB), the University of Bonn, and the German Center for Infection Research (DZIF) have discovered a new lantibiotic, namely epilancin A37. It is produced by staphylococci that colonize the skin and act specifically against their main competitor there, the corynebacteria.
